Tour de France director Christian Prudhomme wants cycling authorities to expedite their investigation of four-time champion Chris Froome.
Froome has been ordered to explain to cycling’s governing body, the Union Cycliste Internationale (UCI), why a urine sample he provided during September’s Vuelta a Epsana showed a concentration of the asthma drug salbutamol that was twice the allowed level.
“We want the situation to be cleared up, to get out of the darkness and ambiguity,” Prudhomme told France Info TV today. “We obviously want an investigation to be conducted, and we don’t want it to last for months and months, so we can have an answer from the UCI as soon as possible next season.”
If found guilty of doping, the Team Sky rider could lose his Vuelta title and be suspended for a long period.
Froome has plans to race in next year’s Tour de France, and Prudhomme wants to avoid a repeat of the scenario that saw Alberto Contador race and win the Giro in 2011 despite a positive test for clenbuterol. His title was later stripped and given to Michele Scarponi after the Court of Arbitration for Sport gave the Spaniard a two-year ban.
Froome won his fourth Tour title this year and followed it with a victory at the Vuelta.
Salbutamol helps expand lung capacity and can be used as a performance-enhancing drug to increase endurance. Salbutamol is classified as a beta-2 agonist and the World Anti-Doping Agency allows it to be taken through inhalation only, in limited amounts.
Team Sky said Froome had to take an increased dosage of the drug without exceeding the permissible dose after he “experienced acute asthma symptoms” during the final week of the Vuelta.
“Salbutamol is not a banned substance,” Prudhomme said. “What matters is the amount taken, that’s why an expert battle will take place, although it looks like the dose found was twice the permitted level.”
You must be logged in to post a comment.